These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Interference of CK-BB isoenzyme in the determination of CK-MB using the immunoinhibition method in patients with pulmonary diseases].
    Author: Vrbica Z, Durović O, Oreb N.
    Journal: Lijec Vjesn; 1997 Nov; 119(10):263-5. PubMed ID: 9531757.
    Abstract:
    An increase in serum creatine kinase-MB (CK-MB) isoenzyme is regarded as a specific indicator of acute myocardial infarction. We analyzed retrospectively the clinical data of 94 patients whose serum creatine kinase MB (CK-MB) was measured with immunoinhibition kit which measures all residual CK activity following inactivation of M-subunit. There were 21 patients with chronic obstructive lung disease (COLD), 17 patients with pneumonia, 17 patients with pulmonary tuberculosis (TBC), 16 patients with non-small cell lung cancer (NSCLC), 10 patients with small cell lung cancer (SCLC), 8 patients with malignancies of other origin (NPL), and 5 patients with chronic heart diseases. The results revealed that serum concentrations of CK-MB in SCLC, NSCLC and TBC were significantly greater than those in other groups (P < 0.1). Clinical examination showed no evidence of myocardial infarction, injury, or tumor involvement of the heart. We assumed that those results are due to interference of the CK-BB isoenzyme in the immunoinhibition method. So we suggest that in clinical practice, markedly elevated levels of CK-MB measured with immunoinhibition kit, after the exclusion of the myocardial injury, may point toward the existence of a malignancy or TBC of the lungs.
    [Abstract] [Full Text] [Related] [New Search]